American BioMed Granted German Patent for Silicone Catheters.

THE WOODLANDS, Texas--(BUSINESS WIRE)--Nov. 18, 1999--

-Company's Proprietary Technologies Gaining Worldwide Recognition-

American BioMed, Inc. (OTC Bulletin Board: ABMI) today announced that its balloon catheter technology has been awarded a patent by the German Federal Court.

Entitled "A Method of Making a Medical Device of Silicone Rubber", the patent file is numbered P35 - 90 566.2 - 45.

This patent adds to the series of 9 patents issued to the Company relating to methods and apparatus utilized in conjunction with the sale and manufacture of balloon catheters in the following countries: United States, Great Britain, France, Germany, Mexico, Italy and Spain. Balloon catheters are used to clear cardiovascular blockages. American BioMed has a family of balloon catheters covered by 10 FDA approvals and 6 CE Mark approvals.

Steven B. Rash, President and Chief Executive Officer, stated, "The Company's one-piece design eliminates glues and ties, providing superior smoothness and preventing the possibility of balloon dislodgment. Additionally, American BioMed's silicone products are an alternative to latex-based products. With intensifying focus on sensitivities and potentially life threatening allergies to latex, silicone technology increasingly is viewed as offering potentially life-saving safety and efficacy advantages."

Mr. Rash continued, "The growing silicone catheter market is currently estimated at over $300 million annually. Our OmniCath atherectomy device, which addresses a potential $500 million market, last week received the CE Mark for quality. Both of these innovative systems will be on display in Dusseldorf, Germany at Medica, the leading international conference for users of cardiovascular products. OmniCath will be officially launched for international sales at this conference."

American BioMed, founded in 1984, utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for use in interventional cardiology, endovascular surgery, minimally invasive surgery and drug delivery therapeutics. The company has over 25 patents and 11 FDA approvals in its product portfolio. American BioMed has over 60 distributors and is represented in over 40 countries.

This release contains forward-looking statement s that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be accompanied by words such as "expect," "anticipate," or "should" that convey the uncertainty of future events or outcomes. These statements are based on assumptions that the Company believes are reasonable; however many important factors could cause the Company's actual results in the future to differ materially from the forward looking statements made herein or in any other documents or oral presentations made by, or on behalf of the Company. Factors which could cause or contribute to such differences include, but are not limited to, the uncertainties associated with governmental regulation, general economic and other market conditions, the results of research and development efforts, the results of pre-clinical and clinical testing, the impact of competitive product development and other risk factors set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties. The Company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.